Does substitution of brand name medications by generics differ between pharmacotherapeutic classes? A population-based cohort study in France

Autor: Robert Bourrel, Agnès Sommet, Alicia Molinier, Vanessa Rousseau, Aurore Palmaro, Jean-Louis Montastruc, Haleh Bagheri
Rok vydání: 2016
Předmět:
Zdroj: European Journal of Clinical Pharmacology. 73:471-477
ISSN: 1432-1041
0031-6970
DOI: 10.1007/s00228-016-2185-z
Popis: The purpose of this study was to measure the rate of substitution failure to generic antiepileptic drugs (AEDs) compared to two other pharmacotherapeutic classes (neuroleptics, beta-blockers). We conducted a cohort study involving beneficiaries of the French health insurance system from January 2009 to November 2012. Substitution failure to generic drugs was estimated by the rate of switchback (i.e. from generic drug back to its branded drug). We selected the patients who had a dispensation of a branded AED for 60 days or more during the 90 days preceding the generic substitution. Cox proportional hazard regression was used to model time to switchback for antiepileptics vs. other therapeutic classes in the 90 days after generic substitution, adjusting for age, gender and polytherapy. The cohort included 6727 patients of whom 1947 were exposed to AEDs, 2398 to neuroleptics and 2382 to beta-blockers. The switchback rate was 62% for AEDs. AED users were more likely to switch back as compared to beta-blocker (crude hazard ratio 1.87; 95% CI 1.68–2.07 for patients under 75) or neuroleptic users. The same observation was made in patients above 75 years (crude hazard ratio 1.36; 95% CI 1.16–1.60). Compared to beta-blocker users, AED users were more likely to switch back to the branded drug, whereas this difference was not observed with neuroleptics. These results could reflect a poor acceptance of switching AEDs to generic compounds in France.
Databáze: OpenAIRE
Externí odkaz: